Celebrex, the only remaining Cox-2 inhibitor drug on the market, has been linked to a two-fold increase in the likelihood of causing a heart attack in patients using the drug. Pfizer, the manufacturer of Celebrex, put a black box warning on the product last August. In spite of the warning, the drug remains on the market. The first Celebrex product liability trial will begin in Alabama this June. The plaintiff suffered a stroke after taking Celebrex.